Clinical indications for this novel medicine will expand.
Sweaty hands, feet, legs, cholinergic urticaria, excess secretions, bronchospasm, colic, pupillary dilation, motion sickness etc
Botanix market cap of $20B on the back of this clinically useful ultra-short acting anticholinergic.
- Forums
- ASX - By Stock
- BOT
- Ann: FDA Approves Sofdra
Ann: FDA Approves Sofdra, page-301
-
-
- There are more pages in this discussion • 201 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.3¢ |
Change
0.013(3.91%) |
Mkt cap ! $606.3M |
Open | High | Low | Value | Volume |
32.0¢ | 34.0¢ | 32.0¢ | $1.465M | 4.421M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 218300 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 367727 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 218300 | 0.330 |
11 | 647750 | 0.325 |
28 | 1353140 | 0.320 |
14 | 1001633 | 0.315 |
22 | 2007358 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 349169 | 9 |
0.340 | 737677 | 10 |
0.345 | 267331 | 10 |
0.350 | 265310 | 8 |
0.355 | 133069 | 6 |
Last trade - 15.31pm 09/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |